Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)

NCT06499948 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Alport Syndrome
Thin Basement Membrane Disease
Alport Nephropathy

Interventions

DRUG: Treatment with Spironolactone followed by Dapagliflozin followed by their combination
DRUG: Treatment with Dapagliflozin followed by Spironolactone followed by their combination

Sponsor

Stefan Lujinschi

Collaborators

[object Object]
[object Object]